Is Ionis Pharmaceuticals Inc (IONS) overvalued? · rev $226.6M
Ionis Pharmaceuticals Inc (IONS) is a biotechnology company listed on NASDAQ.
This page asks whether Ionis Pharmaceuticals Inc (IONS) looks expensive on cached numbers — not a short thesis.
Latest reported IONS revenue for 2024-12-31 was $226.6M. Net income was -$104.3M. Revenue was down 30.2% from 2023-12-31 to 2024-12-31. IONS currently screens at market cap $12.28B.
IONS currently screens at market cap $12.28B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IONS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IONS stock page for the full model, not this heading.
Not investment advice.